CryoPort, Inc. (CYRX)
| Market Cap | 2.87B |
| Revenue (ttm) | 122.21M |
| Net Income (ttm) | -76.81M |
| Shares Out | 45.60M |
| EPS (ttm) | -1.91 |
| PE Ratio | n/a |
| Forward PE | 666.67 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $63.03 |
| Previous Close | $61.56 |
| Change ($) | 1.47 |
| Change (%) | 2.39% |
| Day's Open | 62.57 |
| Day's Range | 61.76 - 65.50 |
| Day's Volume | 324,904 |
| 52-Week Range | 20.21 - 84.97 |
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of 38.10% and 13.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
NASHVILLE, Tenn., May 4, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry...
NASHVILLE, Tenn., April 27, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indus...
New York, New York--(Newsfile Corp. - April 8, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cryoport, Inc. (NASDAQ: CYRX) concerning possible breaches of fiduciary duty. To ob...
NASHVILLE, Tenn., April 6, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indust...
The stock price of CryoPort, a provider of cold chain logistics solutions for biopharmaceutical companies, has seen a large 22% drop over the last five trading days, but we believe the stock, after the ...
NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indust...
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -86.67% and 11.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
NASHVILLE, Tenn., March 1, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indust...
NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indust...
NASHVILLE, Tenn., Feb. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indust...
NASHVILLE, Tenn., Jan. 25, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indust...
NASHVILLE, Tenn., Jan. 20, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indust...
NASHVILLE, Tenn., Jan. 19, 2021 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indust...
Both stocks are in the early stage of a long-term growth trajectory.
Where investors are putting money to work in the Covid vaccine supply chain
CNBC's "Halftime Report" team is joined by Kate Kelly of The New York Times to discuss where investors are putting money along the vaccine supply chain, including cold storage.
With the approval of Yescarta and Kymriah in recent years, you are now seeing unprecedented growth in the CAR-T industry. Logistic providers that support CAR-T and gene therapies are profiting from this...
Logistics of Vaccine Distribution Challenging: Cryoport CEO
Dec.01 -- Cryoport Inc. looks forward to the opportunity to participate in the distribution of the Covid-19 vaccines and admits the logistics will be challenging, Chief Executive Officer Jerrell Shelton...
Cryoport is a strong cold chain platform focused on the fast-growing cell and gene therapy end-market. Company has demonstrated strong execution through COVID and, with recent acquisitions, will become ...
Cryoport's operating model remains insulated via key differentiators in the thermoregulatory logistics domain, with cloud-based integration along the audit chain. Linking with larger players in providin...
Excited about the Covid-19 vaccines from Pfizer and Moderna? You'll be waiting a long time unless the vaccines can be shipped at 94 degrees below zero.
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q3 2020 Results - Earnings Call Transcript
NASHVILLE, Oct. 29, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in life sciences solutions, today announced that the Company will report financial r...
NASHVILLE, Tenn., Oct. 1, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), the life sciences industry's preeminent partner for temperature-controlled supply chain soluti...
Final Trades: CrowdStrike, Cryoport, Industrials & more
The "Halftime Report" traders give their top picks to watch for the second half.
How Cryoport plays a role in the coronavirus fight
CNBC's "Power Lunch" team talks about Cryoport's stock rally with Cryoport CEO Jerrell Shelton.
Cryoport is acquiring Chart's cryobiological business and getting a big boost from one of the giants in private equity.
Cryoport (CYRX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
NASHVILLE, Tenn., Aug. 25, 2020 /PRNewswire/ -- Cryoport, Inc.
NASHVILLE, Tenn., Aug. 21, 2020 /PRNewswire/ -- Cryoport, Inc.
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q2 2020 Results - Earnings Call Transcript
NASHVILLE, Tenn., Aug. 6, 2020 /PRNewswire/ -- Cryoport, Inc.
NASHVILLE, Tenn. and TOKYO, Aug.
NASHVILLE, Tenn., Aug. 3, 2020 /PRNewswire/ -- Cryoport, Inc.
NASHVILLE, Tenn., May 21, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced the pricing on May 20, 2020 of its offering of $100.0 million in aggregate principal amount of 3...
NASHVILLE, Tenn., May 19, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport") today announced its intention to offer, subject to market and other conditions, $100.0 million in aggregate prin...
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q1 2020 Results - Earnings Call Transcript
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q4 2019 Results - Earnings Call Transcript
CryoPort: Profiting From CAR-T
Buckle up, shareholders, and prepare for a miss in Q4.
Cryoport: Cold Chain Is A Hot Business Model
Cryoport, Inc. (CYRX) CEO Jerrell Shelton on Q3 2019 Results - Earnings Call Transcript
Cryoport's (CYRX) CEO Jerry Shelton on Q2 2019 Results - Earnings Call Transcript
Both companies operate in the same market and are of similar size and produce comparable growth rates, yet CryoPort sells at 2.5x the valuation of BioLife.
Chimeric Antigen Receptor/T-Cell Receptor (CAR-T) is powering a fundamental shift for treating deadly cancers.
Cryoport's (CYRX) CEO Jerry Shelton on Q1 2019 Results - Earnings Call Transcript
CYRX earnings call for the period ending December 31, 2018.
About CYRX
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the... [Read more...]
| Industry Integrated Freight & Logistics | Founded 1999 |
| Stock Exchange NASDAQ | Ticker Symbol CYRX |
Financial Performance
In 2020, CryoPort's revenue was $78.70 million, an increase of 131.85% compared to the previous year's $33.94 million. Losses were -$32.69 million, 78.3% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for CryoPort stock is "Strong Buy." The 12-month stock price forecast is 76.13, which is an increase of 20.78% from the latest price.